Suche Struktur Suche
wx_img
Inquiry Form
  1. Home
  2. Osimertinib

Osimertinib

TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.

N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
CM147323
1421372-94-2
2-Bromo-4-methoxyaniline
2-Bromo-4-methoxyaniline
CM252207
32338-02-6
2,4-Difluoro-5-nitroaniline
2,4-Difluoro-5-nitroaniline
CM118614
123344-02-5
3-(2-chloropyrimidin-4-yl)-1H-indole
3-(2-chloropyrimidin-4-yl)-1H-indole
CM148712
945016-63-7
tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate
tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate
CM350166
1802924-13-5
N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine
N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine
CM147322
1421372-67-9